231 related articles for article (PubMed ID: 21874449)
1. Optimization of the Caco-2 permeability assay to screen drug compounds for intestinal absorption and efflux.
Press B
Methods Mol Biol; 2011; 763():139-54. PubMed ID: 21874449
[TBL] [Abstract][Full Text] [Related]
2. Permeability for intestinal absorption: Caco-2 assay and related issues.
Press B; Di Grandi D
Curr Drug Metab; 2008 Nov; 9(9):893-900. PubMed ID: 18991586
[TBL] [Abstract][Full Text] [Related]
3. Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
Lin X; Skolnik S; Chen X; Wang J
Drug Metab Dispos; 2011 Feb; 39(2):265-74. PubMed ID: 21051535
[TBL] [Abstract][Full Text] [Related]
4. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting.
Dahan A; Amidon GL
Am J Physiol Gastrointest Liver Physiol; 2009 Aug; 297(2):G371-7. PubMed ID: 19541926
[TBL] [Abstract][Full Text] [Related]
5. Intestinal absorption mechanism of mirabegron, a potent and selective β₃-adrenoceptor agonist: involvement of human efflux and/or influx transport systems.
Takusagawa S; Ushigome F; Nemoto H; Takahashi Y; Li Q; Kerbusch V; Miyashita A; Iwatsubo T; Usui T
Mol Pharm; 2013 May; 10(5):1783-94. PubMed ID: 23560393
[TBL] [Abstract][Full Text] [Related]
6. Impact of transporters in oral absorption: a case study of in vitro and in vivo organic anion absorption.
Gram LK; Rist GM; Steffansen B
Mol Pharm; 2009; 6(5):1457-65. PubMed ID: 19548658
[TBL] [Abstract][Full Text] [Related]
7. An in vitro and in silico study on the flavonoid-mediated modulation of the transport of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) through Caco-2 monolayers.
Schutte ME; Freidig AP; van de Sandt JJ; Alink GM; Rietjens IM; Groten JP
Toxicol Appl Pharmacol; 2006 Dec; 217(2):204-15. PubMed ID: 16997339
[TBL] [Abstract][Full Text] [Related]
8. In Vitro Intrinsic Permeability: A Transporter-Independent Measure of Caco-2 Cell Permeability in Drug Design and Development.
Fredlund L; Winiwarter S; Hilgendorf C
Mol Pharm; 2017 May; 14(5):1601-1609. PubMed ID: 28329446
[TBL] [Abstract][Full Text] [Related]
9. A new intestinal cell culture model to discriminate the relative contribution of P-gp and BCRP on transport of substrates such as imatinib.
Graber-Maier A; Gutmann H; Drewe J
Mol Pharm; 2010 Oct; 7(5):1618-28. PubMed ID: 20701289
[TBL] [Abstract][Full Text] [Related]
10. In Vitro-In Vivo Extrapolation Scaling Factors for Intestinal P-glycoprotein and Breast Cancer Resistance Protein: Part II. The Impact of Cross-Laboratory Variations of Intestinal Transporter Relative Expression Factors on Predicted Drug Disposition.
Harwood MD; Achour B; Neuhoff S; Russell MR; Carlson G; Warhurst G; Rostami-Hodjegan A
Drug Metab Dispos; 2016 Mar; 44(3):476-80. PubMed ID: 26842595
[TBL] [Abstract][Full Text] [Related]
11. Characterization of efflux transporters involved in distribution and disposition of apixaban.
Zhang D; He K; Herbst JJ; Kolb J; Shou W; Wang L; Balimane PV; Han YH; Gan J; Frost CE; Humphreys WG
Drug Metab Dispos; 2013 Apr; 41(4):827-35. PubMed ID: 23382458
[TBL] [Abstract][Full Text] [Related]
12. Simulating kinetic parameters in transporter mediated permeability across Caco-2 cells. A case study of estrone-3-sulfate.
Rolsted K; Rapin N; Steffansen B
Eur J Pharm Sci; 2011 Oct; 44(3):218-26. PubMed ID: 21888970
[TBL] [Abstract][Full Text] [Related]
13. Zinc finger nuclease-mediated gene knockout results in loss of transport activity for P-glycoprotein, BCRP, and MRP2 in Caco-2 cells.
Sampson KE; Brinker A; Pratt J; Venkatraman N; Xiao Y; Blasberg J; Steiner T; Bourner M; Thompson DC
Drug Metab Dispos; 2015 Feb; 43(2):199-207. PubMed ID: 25388687
[TBL] [Abstract][Full Text] [Related]
14. Role of P-glycoprotein in the intestinal absorption of glabridin, an active flavonoid from the root of Glycyrrhiza glabra.
Cao J; Chen X; Liang J; Yu XQ; Xu AL; Chan E; Wei D; Huang M; Wen JY; Yu XY; Li XT; Sheu FS; Zhou SF
Drug Metab Dispos; 2007 Apr; 35(4):539-53. PubMed ID: 17220245
[TBL] [Abstract][Full Text] [Related]
15. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
Elsby R; Martin P; Surry D; Sharma P; Fenner K
Drug Metab Dispos; 2016 Mar; 44(3):398-408. PubMed ID: 26700956
[TBL] [Abstract][Full Text] [Related]
16. Effects of aripiprazole and its active metabolite dehydroaripiprazole on the activities of drug efflux transporters expressed both in the intestine and at the blood-brain barrier.
Nagasaka Y; Oda K; Iwatsubo T; Kawamura A; Usui T
Biopharm Drug Dispos; 2012 Sep; 33(6):304-15. PubMed ID: 22847220
[TBL] [Abstract][Full Text] [Related]
17. The role of a basolateral transporter in rosuvastatin transport and its interplay with apical breast cancer resistance protein in polarized cell monolayer systems.
Li J; Wang Y; Zhang W; Huang Y; Hein K; Hidalgo IJ
Drug Metab Dispos; 2012 Nov; 40(11):2102-8. PubMed ID: 22855735
[TBL] [Abstract][Full Text] [Related]
18. Development, validation, and application of a novel 7-day Caco-2 cell culture system.
Cai Y; Xu C; Chen P; Hu J; Hu R; Huang M; Bi H
J Pharmacol Toxicol Methods; 2014; 70(2):175-81. PubMed ID: 25034865
[TBL] [Abstract][Full Text] [Related]
19. Use of simulated intestinal fluid for Caco-2 permeability assay of lipophilic drugs.
Fossati L; Dechaume R; Hardillier E; Chevillon D; Prevost C; Bolze S; Maubon N
Int J Pharm; 2008 Aug; 360(1-2):148-55. PubMed ID: 18539418
[TBL] [Abstract][Full Text] [Related]
20. The need for human breast cancer resistance protein substrate and inhibition evaluation in drug discovery and development: why, when, and how?
Poirier A; Portmann R; Cascais AC; Bader U; Walter I; Ullah M; Funk C
Drug Metab Dispos; 2014 Sep; 42(9):1466-77. PubMed ID: 24989889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
